NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy
Portfolio Pulse from
Intellia Therapeutics' genome-editing therapy, nex-z, received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for treating hereditary transthyretin (ATTR) amyloidosis with polyneuropathy. This designation is likely to accelerate the development and review process of the therapy.
November 26, 2024 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intellia Therapeutics' therapy, nex-z, received the FDA's RMAT designation, which could expedite its development and review process, potentially benefiting the company's stock.
The RMAT designation is significant as it can accelerate the development and review process of Intellia's therapy, which is a positive development for the company. This could lead to faster market entry and potential revenue generation, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100